GTBP GT Biopharma

GT Biopharma, Inc. is engages in the development and commercialization of novel immuno-oncology products. Its products include OXS-1550, OXS-1650, OXS-3550, OXS-4550, OXS-1750, OXS-1950, and OXS-2050. The company was founded in 1965 and is headquartered in Tampa, FL.

Company profile

Anthony Cataldo
Fiscal year end
Former names
IRS number

GTBP stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


17 May 21
4 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 27.56M 27.56M 27.56M 27.56M 27.56M 27.56M
Cash burn (monthly) (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn) 1.23M 893.58K
Cash used (since last report) n/a n/a n/a n/a 5.08M 3.7M
Cash remaining n/a n/a n/a n/a 22.47M 23.86M
Runway (months of cash) n/a n/a n/a n/a 18.3 26.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
22 Dec 20 Weldon Steven W Common Stock Sell Dispose S No Yes 0.4 47,978 19.19K 3,720,000
21 Dec 20 Weldon Steven W Common Stock Sell Dispose S No Yes 0.34 35,722 12.15K 3,767,978
21 Dec 20 Weldon Steven W Common Stock Sell Dispose S No Yes 0.33 50,000 16.5K 3,803,700
21 Dec 20 Weldon Steven W Common Stock Sell Dispose S No Yes 0.3 50,000 15K 3,853,700
18 Dec 20 Weldon Steven W Common Stock Sell Dispose S No Yes 0.3 50,000 15K 3,903,700
17 Dec 20 Weldon Steven W Common Stock Sell Dispose S No Yes 0.31 50,000 15.5K 3,953,700
17 Dec 20 Weldon Steven W Common Stock Sell Dispose S No Yes 0.3 50,000 15K 4,003,700
16 Dec 20 Weldon Steven W Common Stock Sell Dispose S No Yes 0.3 50,000 15K 4,053,700
15 Dec 20 Weldon Steven W Common Stock Sell Dispose S No Yes 0.32 50,000 16K 4,103,700
15 Dec 20 Weldon Steven W Common Stock Sell Dispose S No Yes 0.3 50,000 15K 4,153,700

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

  • Our business is at an early stage of development and we may not develop therapeutic products that can be commercialized.
  • We have a history of operating losses and we expect to continue to incur losses for the foreseeable future and we may never generate revenue or achieve profitability.
  • We will need additional capital to conduct our operations and develop our products, and our ability to obtain the necessary funding is uncertain.
  • Research and Development Investment
  • We have identified material weaknesses in our internal controls over financial reporting and have not yet remedied these weaknesses. If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.
  • Our intellectual property may be compromised.
  • Claims that we infringe the intellectual property rights of others may prevent or delay our drug discovery and development efforts.
  • We may desire, or be forced, to seek additional licenses to use intellectual property owned by third parties, and such licenses may not be available on commercially reasonable terms or at all.
  • The patent protection covering some of our product candidates may be dependent on third parties, who may not effectively maintain that protection.
  • We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time- consuming and unsuccessful.
  • If we are unsuccessful in obtaining or maintaining patent protection for intellectual property in development, our business and competitive position would be harmed.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • If we fail to meet our obligations under our license agreements, we may lose our rights to key technologies on which our business depends.
  • We will have to hire additional executive officers and employees to operate our business. If we are unable to hire qualified personnel, we may not be able to implement our business strategy.
  • We depend on key personnel for our continued operations and future success, and a loss of certain key personnel could significantly hinder our ability to move forward with our business plan.
  • We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
  • Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause our business to suffer.
  • Our reliance on the activities of our non-employee consultants, research institutions and scientific contractors, whose activities are not wholly within our control, may lead to delays in development of our proposed products.
  • It may take longer to complete our clinical trials than we project, or we may not be able to complete them at all.
  • Clinical drug development is costly, time-consuming and uncertain, and we may suffer setbacks in our clinical development program that could harm our business.
  • If we experience delays or difficulties in the enrollment of patients in clinical trials, those clinical trials could take longer than expected to complete and our receipt of necessary regulatory approvals could be delayed or prevented.
  • We have limited clinical testing and regulatory capabilities, and human clinical trials are subject to extensive regulatory requirements, very expensive, time-consuming and difficult to design and implement. Our products may fail to achieve necessary safety and efficacy endpoints during clinical trials, which may limit our ability to generate revenues from therapeutic products.
  • Obtaining regulatory approval even after clinical trials that are believed to be successful is an uncertain process.
  • We will continue to be subject to extensive FDA regulation following any product approvals, and if we fail to comply with these regulations, we may suffer a significant setback in our business.
  • Many of our business practices are subject to scrutiny and potential investigation by regulatory and government enforcement authorities, as well as to lawsuits brought by private citizens under federal and state laws. We could become subject to investigations, and our failure to comply with applicable law or an adverse decision in lawsuits may result in adverse consequences to us. If we fail to comply with U.S. healthcare laws, we could face substantial penalties and financial exposure, and our business, operations and financial condition could be adversely affected.
  • We may not be successful in our efforts to build a pipeline of product candidates.
  • Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
  • We may expend our limited resources to pursue a particular product candidate or indication that does not produce any commercially viable products and may fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • Our products may be expensive to manufacture, and they may not be profitable if we are unable to control the costs to manufacture them.
  • We currently lack manufacturing capabilities to produce our therapeutic product candidates at commercial-scale quantities and do not have an alternate manufacturing supply, which could negatively impact our ability to meet any future demand for the product.
  • To be successful, our proposed products must be accepted by the healthcare community, which can be very slow to adopt or unreceptive to new technologies and products.
  • Our business is based on novel technologies that are inherently expensive and risky and may not be understood by or accepted in the marketplace, which could adversely affect our future value.
  • Our competition includes fully integrated biotechnology and pharmaceutical companies that have significant advantages over us.
  • If competitors develop and market products that are more effective, safer or less expensive than our product candidates or offer other advantages, our commercial prospects will be limited.
  • If we are unable to keep up with rapid technological changes in our field or compete effectively, we will be unable to operate profitably.
  • We may not be able to obtain third-party patient reimbursement or favorable product pricing, which would reduce our ability to operate profitably.
  • We may be subject to litigation that will be costly to defend or pursue and uncertain in its outcome.
  • We are exposed to the risk of liability claims, for which we may not have adequate insurance.
  • We could be subject to product liability lawsuits based on the use of our product candidates in clinical testing or, if obtained, following marketing approval and commercialization. If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to cease clinical testing or limit commercialization of our product candidates.
  • We rely on third parties to conduct preclinical and clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.
  • We currently have no marketing and sales force. If we are unable to establish effective marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to effectively market and sell our product candidates, if approved, or generate product revenues.
  • Our business and operations would suffer in the event of system failures.
  • Our operations are vulnerable to interruption by natural disasters, power loss, terrorist activity and other events beyond our control, the occurrence of which could materially harm our business.
  • We have not held regular annual meetings in the past, and if we are required by the Delaware Court of Chancery to hold an annual meeting pursuant to Section 211(c) of the Delaware General Corporation Law, or the DGCL, it could result in the unanticipated expenditure of funds, time and other Company resources.
  • There has been a limited public market for our common stock, and we do not know whether one will develop to provide you adequate liquidity. Furthermore, the trading price for our common stock, should an active trading market develop, may be volatile and could be subject to wide fluctuations in per-share price.
  • Because our common stock may be deemed a low-priced “penny” stock, an investment in our common stock should be considered high- risk and subject to marketability restrictions.
  • If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
  • Anti-takeover provisions may limit the ability of another party to acquire us, which could cause our stock price to decline.
  • We do not currently or for the foreseeable future intend to pay dividends on our common stock.
Management Discussion
  • During the three months ended March 31, 2021 and 2020, we incurred $1,640,000 and $324,000 research and development expenses, an increase of $1,316,000. Research and development costs increased due primarily to the issuance of 189,753 shares of common stock as payment of a fee valued at $1,355,000. We anticipate our direct clinical costs to increase in the remainder of 2021 upon the continuation of a phase one/two clinical trial of our most advanced TriKe product candidate, OXS-3550.
  • During the three months ended March 31, 2021 and 2020, we incurred $27,362,000 and $746,000 of selling, general and administrative expenses.  The increase in selling, general and administrative expenses is primarily attributable the increase in stock based compensation. In the period ended March 31, 2021 we incurred $21,535,000 of stock based compensation, we incurred no such expenses during 2020.
  • Change in fair value of derivative liability was a gain of $21,000 for the three months ended March 31, 2021 and we had no such gain or loss for the same period in 2020.
Content analysis
H.S. sophomore Avg
New words: Agency, alternative, answer, answered, arisen, ASU, award, Bank, beginning, bifurcation, Binomial, CEO, CFO, chose, closure, compensatory, Concurrent, constitute, corroborated, coverage, decided, deducting, demand, denying, derecognition, disability, discontinued, display, disrupted, dividend, duration, electronic, eligible, embedded, Emerging, entry, equivalent, ErgoFlex, European, FDA, Force, foregoing, fractional, gain, good, governmental, Gregory, hand, handled, harm, hierarchy, host, intrinsic, joint, longer, lump, magnitude, maker, mandatorily, memorializing, merit, milestone, minimize, modified, occurred, ordinary, outbreak, pandemic, party, past, predict, premium, prepaid, prop, provision, recurring, remotely, rendered, requisite, Restated, restatement, retroactively, retrospective, reverse, rounded, scheduled, segment, shareholder, Sheffield, single, space, spending, split, spread, submission, Subtopic, sum, supported, supporting, Task, team, transfer, Translational, underwriting, Union, unissued, unreimbursed, unsecured, unvested, vacation, Ventura, vigorously, volatility, wholly, withholding, world, worldwide, yield
Removed: accrual, accrue, achievement, acquired, acquisition, annually, apparent, area, asset, book, CA, capitalized, compound, conform, consent, consequential, consistently, consisting, contemplated, continuing, conveyed, culmination, customary, Cytovance, decreased, deemed, defense, defer, Deposit, depreciated, Depreciation, developing, directly, discounted, diversity, dividing, economic, Efficient, element, Empery, employee, enacted, equipment, estate, evaluate, evident, executory, existing, experience, expertise, expression, favorable, filing, Fixed, flow, found, generation, geographic, GMP, goodwill, group, growth, Hepalink, highly, idea, impaired, impairment, incorporate, indefinite, indemnification, independent, indirectly, inherent, institutional, insured, intangible, integrity, investor, involvement, Keystone, leasehold, licensed, licensee, liquid, lived, lower, LP, machinery, maintenance, making, marketable, Master, measurement, methodology, microbial, monitored, negative, objectivity, offer, original, origination, patent, patentable, patented, performed, periodically, plant, positive, preparing, prepay, production, projected, pursuing, readily, real, realized, receivable, recombinant, recoverable, registration, relate, relief, rent, response, reviewed, secured, security, selection, senior, separate, shorter, statutory, Steven, substantive, table, technological, testing, thousand, timing, twenty, typically, undiscounted, utility, utilizing, variable, viable, weighted, Weldon